Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Spinocerebellar Ataxia Type 17

Yasuko Toyoshima  1 , Osamu Onodera  2 , Mitsunori Yamada  3 , Shoji Tsuji  4 , Hitoshi Takahashi  5
Margaret P Adam, Jerry Feldman, Ghayda M Mirzaa, Roberta A Pagon, Stephanie E Wallace, Anne Amemiya
, editors.
In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
[updated ].
Affiliations
Free Books & Documents
Review

Spinocerebellar Ataxia Type 17

Yasuko Toyoshima et al.
Free Books & Documents

Excerpt

Clinical characteristics: Spinocerebellar ataxia type 17 (SCA17) is characterized by ataxia, dementia, and involuntary movements, including chorea and dystonia. Psychiatric symptoms, pyramidal signs, and rigidity are common. The age of onset ranges from three to 55 years. Individuals with full-penetrance alleles develop neurologic and/or psychiatric symptoms by age 50 years. Ataxia and psychiatric abnormalities are frequently the initial findings, followed by involuntary movement, parkinsonism, dementia, and pyramidal signs. Brain MRI shows variable atrophy of the cerebrum, brain stem, and cerebellum. The clinical features correlate with the length of the polyglutamine expansion but are not absolutely predictive of the clinical course.

Diagnosis/testing: The diagnosis of SCA17 is established in a proband by identification of an abnormal CAG/CAA repeat expansion in TBP. Affected individuals usually have more than 41 repeats. The CAA and CAG codons both encode glutamine residues resulting in a pathogenic polyglutamine expansion.

Management: Treatment of manifestations: Psychotropic medications for psychiatric issues, anti-seizure medication for seizures (ASM); botulinum toxin injections for dystonia; adaptation of the environment to accommodate dementia.

Prevention of secondary complications: Side effects of psychotropic medications and ASMs may require total or intermittent discontinuation of the treatment or reduction in dose.

Surveillance: Annual or semiannual evaluation by a neurologist or more frequently if symptoms are progressing rapidly.

Agents/circumstances to avoid: Sedative/hypnotic agents, such as ethanol or certain medications, may exacerbate incoordination.

Genetic counseling: SCA17 is inherited in an autosomal dominant manner. Offspring of affected individuals are at a 50% risk of inheriting the expanded TBP allele. The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be precisely predicted by family history or size of expansion. Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible if the diagnosis has been established in an affected family member by molecular genetic testing.

PubMed Disclaimer

References

    1. Alendar A, Euljkovic B, Savic D, Djarmati A, Keckarevic M, Ristic A, Dragasevic N, Kosic V, Romac S. Spinocerebellar ataxia type 17 in the Yugoslav population. Acta Neurol Scand. 2004;109:185–7. - PubMed
    1. Alibardi A, Squitieri F, Fattapposta F, Missori P, Pierelli F, Trompetto C, Curra A. Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene. Parkinsonism Relat Disord. 2014;20:678–9. - PubMed
    1. Bauer P, Laccone F, Rolfs A, Wullner U, Bosch S, Peters H, Liebscher S, Scheible M, Epplen JT, Weber BH, Holinski-Feder E, Weirich-Schwaiger H, Morris-Rosendahl DJ, Andrich J, Riess O. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J Med Genet. 2004;41:230–2. - PMC - PubMed
    1. Bech S, Petersen T, Norremolle A, Gjedde A, Ehlers L, Eiberg H, Hjermind LE, Hasholt L, Lundorf E, Nielsen JE. Huntington’s disease-like and ataxia syndromes: identification of a family with a de novo SCA17/TBP mutation. Parkinsonism Relat Disord. 2010;16:12–5. - PubMed
    1. Cellini E, Forleo P, Nacmias B, Tedde A, Bagnoli S, Piacentini S, Sorbi S. Spinocerebellar ataxia type 17 repeat in patients with Huntington's disease-like and ataxia. Ann Neurol. 2004;56:163–4. - PubMed

LinkOut - more resources